National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Genetic Variation (SNPs)
< Back to Main
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
View/Print PowerPoint  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Slide 31 : Arylamines and Bladder Cancer previousnext

Some workers in the dye industry, after occupational exposure to arylamines, develop an increased risk of bladder cancer. Scientists suspect that SNPs may be involved.

In the liver, arylamines can have two fates, because there are two enzymes available to act on them.

An acetylator enzyme can deactivate arylamines, converting them into nonreactive compounds that are safely removed from the body.

Or arylamines can be activated by a deaminator enzyme in the liver to become precarcinogens that are carried to the bladder. There they are converted into carcinogens.

Arylamines and Bladder Cancer

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov